Reason for request
First listing
Summary of opinion
Favourable opinion for reimbursement “for diagnostic use only, in adults and children aged 2 years and older for contrast-enhanced magnetic resonance imaging (MRI) to improve detection and visualisation of pathologies with disruption of the blood-brain-barrier (BBB) and/or abnormal vascularity of:
- the brain, spine, and associated tissues of the central nervous system (CNS);
- the liver, kidney, pancreas, breast, lung, prostate, and musculoskeletal system.
ELUCIREM should be used only when diagnostic information is essential and not available with unenhanced MRI”.
Clinical Benefit
| Substantial |
The Committee deems that the clinical benefit of ELUCIREM (gadopiclenol) 0.5 mmol/mL solution for injection is substantial in the MA indications. |
Clinical Added Value
| no clinical added value |
Considering:
- evidence of a non-inferiority of MRI with injection of ELUCIREM (gadopiclenol) at a dose of 05 mmol/kg compared to injection of gadobutrol at a dose of 0.1 mmol/kg, on 3 coprimary endpoints for visualisation of lesions in the CNS and body, in the PICTURE and PROMISE studies conducted in adults,
- the pharmacokinetic profile in children similar to that observed in adults,
but:
- the absence of comparison in the paediatric study and robust efficacy and safety data,
- the limited safety data in terms of follow-up duration, limiting monitoring of the occurrence of adverse events (AE) such as retention of gadolinium in the brain or nephrogenic systemic fibrosis (NSF), an AE associated with the administration of a gadolinium-based contrast agent, the symptoms of which can develop several weeks to several months after its administration,
the Committee deems that ELUCIREM (gadopiclenol) 0.5 mmol/mL solution for injection provides no clinical added value (CAV V) compared with gadobutrol. |
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
p9eHR178tHUV9WbL
Listen
